Themis Medicare Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare's board met on February 13, 2026 and approved unaudited standalone and consolidated results for Q3 FY26 (quarter ended Dec 31, 2025) and the nine-month period. Standalone Q3 revenue came in at ₹9,013.32 lakhs (down from ₹9,380.63 lakhs a year ago), with a profit after tax of ₹457.81 lakhs versus ₹308.12 lakhs in the year-ago quarter. However, on a nine-month basis, the company swung to a standalone loss of ₹1,615.11 lakhs from a profit of ₹3,166.63 lakhs last year, hurt partly by a ₹86.53 lakh exceptional charge for new Labour Codes and a ₹129.39 lakh write-off in Q2 related to the dissolution of UK subsidiary Carpo Medicals Limited. Consolidated Q3 showed a stronger PAT of ₹1,009.36 lakhs (vs ₹51.93 lakhs), supported by share of profits from associates including Gujarat Themis Biosyn Limited. The board also approved a proposal to issue convertible equity warrants of up to 4.99% of paid-up capital (about 45.95 lakh shares) to Promoters/Promoter Group via preferential allotment, and an inter-se transfer of up to 3% of GTBL shares within the promoter group at market price.
Short-term: Mildly positive on better Q3 standalone profit and turnaround in consolidated profitability. Medium-term: Dilution risk from the proposed warrants (up to ~4.99% to promoters) and continued nine-month losses are key concerns for minority shareholders; GTBL transfer is internal to the promoter group and does not change overall control.